From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes a recent transition from being a candidate to being an approved/specified/listed/etc. inside buyers' systems, such that future business can arrive without discrete selling, and that this is new and the volume is ahead. Scan the transcript. Management talks about partnerships, products, AEP, etc. They mention "leading health system partnerships to support the launch of our PPO products, including Cedars-Sinai, Scripps Health and Hoag Memorial." That's about partnerships, not necessarily being placed into a buyer's system. They talk about product features, benefits, etc. They talk about Star Ratings, but that's not about being in a pathway. They talk about DCE (Direct Contracting Entity) - that's a program where they take risk for Medicare beneficiaries. That could be a form of being in a reimbursement pathway? But they say it's early, they are still learning, and they haven't broken out results. They mention "we did receive another couple of months of CMS claims run-out data" and "2Q performance appears to be modestly better" but "third quarter DCE MLR continues to trend greater than 100%" and they need more quarters to see profitability. So DCE is not yet proven, and it's not described as a new access that will bring volume without selling. They also talk about new market launches, but that's just expansion. The question is about a specific phenomenon: the company has moved from candidate to default inside a routine purchasing pathway. For example, being added to a formulary, being qualified onto a roster, etc. In this transcript, I don't see any such description. They talk about partnerships with health systems, but that's not necessarily a buyer-side system. They talk about product launches, but that's just selling. They talk about AEP (Annual Election Period) which is a selling period. They don't mention being placed on any approved vendor list, being written into specifications, etc. The only possible thing is DCE, but that's a program they are participating in, not a status that makes future business automatic. And they say it's early and not yet profitable. So no. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.